My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 339

    1.

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

    Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

    Diabetes Care. 2005 May;28(5):1083-91.PMID: 15855571 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

    Diabetes Care. 2005 May;28(5):1092-100.PMID: 15855572 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group.

    Diabetes Care. 2004 Nov;27(11):2628-35.PMID: 15504997 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

    Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.

    Clin Ther. 2007 Jan;29(1):139-53.PMID: 17379054 [PubMed - indexed for MEDLINE]Related articles

    5.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    6.

    Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

    Curr Med Res Opin. 2009 Jan;25(1):65-75.PMID: 19210140 [PubMed - indexed for MEDLINE]Related articles

    7.

    The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

    Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M.

    Diabetes Technol Ther. 2007 Aug;9(4):317-26.PMID: 17705687 [PubMed - indexed for MEDLINE]Related articles

    8.

    Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

    Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

    Diabetes Obes Metab. 2006 Jul;8(4):436-47.PMID: 16776751 [PubMed - indexed for MEDLINE]Related articles

    9.

    The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

    Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

    Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896. PMID: 17404349 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.

    Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.

    Horm Metab Res. 2006 Dec;38(12):838-44.PMID: 17163361 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

    Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD.

    Diabetes Care. 2003 Aug;26(8):2370-7.PMID: 12882864 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

    Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.

    Clin Ther. 2009 Apr;31(4):806-15.PMID: 19446153 [PubMed - indexed for MEDLINE]Related articles

    13.

    Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.

    Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG.

    Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):483-91.PMID: 16634116 [PubMed - indexed for MEDLINE]Related articles

    14.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    15.

    Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

    Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

    Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD.

    Diabetes Obes Metab. 2006 Jul;8(4):419-28.PMID: 16776749 [PubMed - indexed for MEDLINE]Related articles

    17.

    Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.

    Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D.

    Diabetes Technol Ther. 2005 Jun;7(3):467-77.PMID: 15929678 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.

    Diabetes Care. 2007 Jun;30(6):1487-93. Epub 2007 Mar 12.PMID: 17353504 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.

    Clin Ther. 2008 May;30(5):858-67.PMID: 18555933 [PubMed - indexed for MEDLINE]Related articles

    20.

    Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

    Iltz JL, Baker DE, Setter SM, Keith Campbell R.

    Clin Ther. 2006 May;28(5):652-65. Review.PMID: 16861088 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity